Juniper Pharmaceuticals, Inc., formerly Columbia Laboratories, Inc., is a women's health therapeutic company focused on developing intra-vaginal therapeutics that addresses the medical needs in women's health. The Company operates through two segments: product and service. The product segment includes supply chain management for CRINONE. The product segment also includes the royalty stream the Company receives from Allergan for CRINONE sales in the United States, as well as the development of new product candidates. The service segment includes pharmaceutical development, clinical trial manufacturing and advanced analytical and consulting services for the its customers, as well as characterizing and developing pharmaceutical product candidates for its internal programs, and managing the preclinical and clinical manufacturing of COL-1077 and its intra-vaginal ring (IVR). Its product and product development programs include CRINONE 8%, COL-1077, JNP-0101, JNP-0101 and JNP-0301.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drugs - Generic
- Sub-Industry: N/A
- Symbol: NASDAQ:JNP
- CUSIP: N/A
- Web: www.juniperpharma.com
- Market Cap: $45.54 million
- Outstanding Shares: 10,843,000
- 50 Day Moving Avg: $4.22
- 200 Day Moving Avg: $4.93
- 52 Week Range: $3.65 - $8.00
Sales & Book Value:
- Trailing P/E Ratio: 7.43
- Foreward P/E Ratio: -9.13
- P/E Growth: 0.00
- Annual Revenue: $55.34 million
- Price / Sales: 0.82
- Book Value: $3.59 per share
- Price / Book: 1.17
- EBIDTA: $7.46 million
- Net Margins: -7.44%
- Return on Equity: -9.68%
- Return on Assets: -6.47%
- Debt-to-Equity Ratio: 0.08%
- Current Ratio: 1.73%
- Quick Ratio: 1.42%
- Average Volume: 49,034 shs.
- Beta: 0.25
- Short Ratio: 2.62
Frequently Asked Questions for Juniper Pharmaceuticals (NASDAQ:JNP)
What is Juniper Pharmaceuticals' stock symbol?
Juniper Pharmaceuticals trades on the NASDAQ under the ticker symbol "JNP."
How were Juniper Pharmaceuticals' earnings last quarter?
Juniper Pharmaceuticals Inc (NASDAQ:JNP) released its earnings results on Thursday, May, 4th. The company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of ($0.09) by $0.04. The firm had revenue of $11.25 million for the quarter, compared to the consensus estimate of $11.27 million. Juniper Pharmaceuticals had a negative return on equity of 9.68% and a negative net margin of 7.44%. View Juniper Pharmaceuticals' Earnings History.
Where is Juniper Pharmaceuticals' stock going? Where will Juniper Pharmaceuticals' stock price be in 2017?
3 brokers have issued 12-month price targets for Juniper Pharmaceuticals' shares. Their forecasts range from $6.75 to $12.00. On average, they anticipate Juniper Pharmaceuticals' stock price to reach $9.38 in the next twelve months. View Analyst Ratings for Juniper Pharmaceuticals.
Are investors shorting Juniper Pharmaceuticals?
Juniper Pharmaceuticals saw a drop in short interest during the month of April. As of April 13th, there was short interest totalling 132,588 shares, a drop of 18.7% from the March 31st total of 163,022 shares. Based on an average trading volume of 37,083 shares, the short-interest ratio is currently 3.6 days.
Who are some of Juniper Pharmaceuticals' key competitors?
Some companies that are related to Juniper Pharmaceuticals include pSivida Corp. (PSDV), Galectin Therapeutics (GALT), Sophiris Bio (SPHS), Kalvista Pharmaceuticals (KALV), Lipocine (LPCN), Innocoll Holdings PLC (INNL), SCYNEXIS (SCYX), Evoke Pharma (EVOK), Fibrocell Science (FCSC), Sonoma Pharmaceuticals (SNOA), Celator Pharmaceuticals (CPXX), NephroGenex (NRX), Parnell Pharmaceuticals Holdings Ltd (PARN) and Sagent Pharmaceuticals (SGNT).
Who are Juniper Pharmaceuticals' key executives?
Juniper Pharmaceuticals' management team includes the folowing people:
- James A. Geraghty, Independence Chairman of the Board
- Jeffrey E. Young, Chief Financial Officer, Vice President - Finance, Treasurer, Secretary
- Nikin Patel, Chief Operating Officer, Director
- Bridget A. Martell, Chief Medical Officer
- Frank C. Condella Jr., Non-Executive Director
- Frank Murdoch Armstrong, Independent Director
- Cristina Csimma Pharm.D., Independent Director
- Mary Ann Gray Ph.D., Independent Director
- Ann Merrifield, Independent Director
Who owns Juniper Pharmaceuticals stock?
Juniper Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (4.16%), Heartland Advisors Inc. (3.69%), Renaissance Technologies LLC (2.85%), Wells Fargo & Company MN (1.16%), Algert Global LLC (1.00%) and AWM Investment Company Inc. (0.92%). Company insiders that own Juniper Pharmaceuticals stock include Alicia Secor, C Ann Merrifield, Frank Condella Jr, Frank M Armstrong, George Elston, James A Geraghty and Nikin Patel. View Institutional Ownership Trends for Juniper Pharmaceuticals.
Who sold Juniper Pharmaceuticals stock? Who is selling Juniper Pharmaceuticals stock?
Who bought Juniper Pharmaceuticals stock? Who is buying Juniper Pharmaceuticals stock?
Juniper Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including AWM Investment Company Inc., Renaissance Technologies LLC, Algert Global LLC, KCG Holdings Inc., Goldman Sachs Group Inc., Morgan Stanley, TFS Capital LLC and Acadian Asset Management LLC. Company insiders that have bought Juniper Pharmaceuticals stock in the last two years include Alicia Secor, C Ann Merrifield, Frank Condella Jr, Frank M Armstrong, George Elston, James A Geraghty and Nikin Patel. View Insider Buying and Selling for Juniper Pharmaceuticals.
How do I buy Juniper Pharmaceuticals stock?
Shares of Juniper Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Juniper Pharmaceuticals' stock price today?
MarketBeat Community Rating for Juniper Pharmaceuticals (NASDAQ JNP)MarketBeat's community ratings are surveys of what our community members think about Juniper Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Juniper Pharmaceuticals stock can currently be purchased for approximately $4.20.
Earnings History for Juniper Pharmaceuticals (NASDAQ:JNP)Earnings History by Quarter for Juniper Pharmaceuticals (NASDAQ:JNP)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/4/2017||Q1 2017||($0.09)||($0.13)||$11.27 million||$11.25 million||View||Listen|
|3/7/2017||Q4 2016||$0.45||$0.88||$15.33 million||$20.93 million||View||Listen|
|11/15/2016||Q3 2016||($0.15)||$0.02||$10.58 million||$11.56 million||View||N/A|
|8/4/2016||Q216||($0.08)||($0.16)||$9.49 million||$11.89 million||View||N/A|
|5/4/2016||Q116||($0.08)||$0.03||$9.13 million||$12.10 million||View||N/A|
|3/10/2016||Q415||($0.02)||($0.19)||$7.89 million||$7.60 million||View||N/A|
|11/10/2015||Q315||($0.05)||$0.09||$7.10 million||$11.50 million||View||N/A|
|8/4/2015||Q215||($0.02)||($0.03)||$8.35 million||$10.20 million||View||N/A|
|5/6/2015||Q115||$0.04||$0.07||$7.80 million||$8.30 million||View||N/A|
|3/18/2015||Q414||$0.07||($0.05)||$7.93 million||$7.30 million||View||N/A|
|10/28/2014||Q314||$0.12||$0.34||$9.74 million||$11.50 million||View||N/A|
|3/5/2014||Q413||$0.08||$7.10 million||$7.80 million||View||N/A|
|11/7/2013||Q313||$0.16||$0.20||$6.75 million||$7.10 million||View||N/A|
|8/7/2013||Q2 2013||$0.02||$0.03||$6.50 million||$7.02 million||View||N/A|
|5/9/2013||Q1 2013||$0.03||$0.01||$6.50 million||$6.30 million||View||N/A|
|3/14/2013||Q4 2012||$0.02||$0.03||$7.60 million||$6.10 million||View||N/A|
Earnings Estimates for Juniper Pharmaceuticals (NASDAQ:JNP)
Current Year EPS Consensus Estimate: $-0.45 EPS
Next Year EPS Consensus Estimate: $-0.46 EPS
Dividend History for Juniper Pharmaceuticals (NASDAQ:JNP)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Juniper Pharmaceuticals (NASDAQ:JNP)
Insider Ownership Percentage: 11.60%Insider Trades by Quarter for Juniper Pharmaceuticals (NASDAQ:JNP)
Institutional Ownership Percentage: 33.12%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|3/17/2017||James A Geraghty||Director||Buy||2,000||$4.82||$9,640.00|| |
|9/13/2016||James A Geraghty||Director||Buy||2,000||$5.97||$11,940.00|| |
|8/31/2016||George Elston||CFO||Buy||1,000||$5.50||$5,500.00|| |
|8/26/2016||C Ann Merrifield||Director||Buy||2,000||$5.63||$11,260.00|| |
|8/25/2016||Alicia Secor||Insider||Buy||5,000||$5.75||$28,750.00|| |
|8/23/2016||James A Geraghty||Director||Buy||7,000||$5.96||$41,720.00|| |
|12/4/2015||C Ann Merrifield||Director||Buy||1,600||$12.14||$19,424.00|| |
|11/19/2015||Nikin Patel||COO||Buy||5,000||$11.82||$59,100.00|| |
|11/18/2015||Frank Condella Jr||CEO||Buy||5,000||$11.68||$58,400.00|| |
|8/14/2015||C Ann Merrifield||Director||Buy||3,000||$9.90||$29,700.00|| |
|6/15/2015||Frank M Armstrong||Director||Buy||1,255||$7.95||$9,977.25|| |
|6/9/2015||Nikin Patel||COO||Buy||13,500||$7.52||$101,520.00|| |
|5/8/2015||Frank Condella Jr||CEO||Buy||10,000||$7.36||$73,600.00|| |
|11/20/2014||Donald H Hunter||Director||Buy||1,000||$5.98||$5,980.00|| |
|8/13/2014||Frank Condella Jr||CEO||Buy||10,000||$5.98||$59,800.00|| |
|5/5/2014||Frank Condella Jr||CEO||Buy||10,000||$6.65||$66,500.00|| |
Headline Trends for Juniper Pharmaceuticals (NASDAQ:JNP)
Latest Headlines for Juniper Pharmaceuticals (NASDAQ:JNP)
|Juniper Pharmaceuticals Inc (JNP) Issues Quarterly Earnings Results, Misses Estimates By $0.04 EPS|
www.americanbankingnews.com - May 8 at 6:04 PM
|Edited Transcript of JNP earnings conference call or presentation 4-May-17 12:30pm GMT|
finance.yahoo.com - May 8 at 5:44 PM
|HC Wainwright Reaffirms Hold Rating for Juniper Pharmaceuticals Inc (JNP)|
www.americanbankingnews.com - May 5 at 5:38 PM
|Juniper Pharmaceuticals posts 1Q loss|
finance.yahoo.com - May 4 at 12:16 PM
|$11.27 Million in Sales Expected for Juniper Pharmaceuticals Inc (JNP) This Quarter|
www.americanbankingnews.com - May 4 at 1:37 AM
|Juniper Pharmaceuticals Inc (JNP) Expected to Post Earnings of -$0.09 Per Share|
www.americanbankingnews.com - May 4 at 1:36 AM
|Juniper Pharmaceuticals Inc (JNP) Receives Average Rating of "Hold" from Analysts|
www.americanbankingnews.com - May 3 at 12:58 AM
|Juniper Pharmaceuticals (JNP) Receiving Somewhat Critical News Coverage, Analysis Shows|
www.americanbankingnews.com - May 1 at 4:48 PM
|Juniper Pharmaceuticals Inc (JNP) Short Interest Down 18.7% in April|
www.americanbankingnews.com - April 30 at 1:03 PM
|Juniper Pharmaceuticals Inc (JNP) Expected to Post Quarterly Sales of $11.27 Million|
www.americanbankingnews.com - April 30 at 10:14 AM
| Analysts Expect Juniper Pharmaceuticals Inc (JNP) to Announce -$0.09 Earnings Per Share|
www.americanbankingnews.com - April 28 at 10:02 AM
|Juniper Pharmaceuticals to Report First Quarter 2017 Results on May 4, 2017|
finance.yahoo.com - April 28 at 9:47 AM
|Juniper Pharmaceuticals (JNP) Receives Media Impact Rating of -0.25|
www.americanbankingnews.com - April 27 at 3:06 PM
|Juniper Pharmaceuticals (JNP) Receives Coverage Optimism Score of -0.06|
www.americanbankingnews.com - April 21 at 9:20 PM
|Juniper Pharmaceuticals (JNP) Earning Favorable News Coverage, Analysis Finds|
www.americanbankingnews.com - April 17 at 9:09 AM
|Juniper Pharmaceuticals Inc (JNP) Upgraded by TheStreet to "C"|
www.americanbankingnews.com - April 17 at 12:52 AM
|Krensavage Asset Management Urges Juniper Pharmaceuticals to Consider Sale of Company|
finance.yahoo.com - April 12 at 8:51 AM
|ETFs with exposure to Juniper Pharmaceuticals, Inc. : April 10, 2017|
finance.yahoo.com - April 10 at 5:45 PM
|Zacks: Analysts Anticipate Juniper Pharmaceuticals Inc (JNP) Will Announce Quarterly Sales of $11.27 Million|
www.americanbankingnews.com - April 8 at 8:00 AM
|Juniper Pharmaceuticals Inc (JNP) Expected to Announce Earnings of -$0.09 Per Share|
www.americanbankingnews.com - April 7 at 12:13 AM
|Juniper Pharmaceuticals Inc (JNP) Receives Consensus Recommendation of "Hold" from Brokerages|
www.americanbankingnews.com - April 5 at 4:54 PM
|Juniper Pharmaceuticals Recognized for Board Diversity at Get Konnected! 9th Anniversary Event|
finance.yahoo.com - March 29 at 10:25 AM
|Juniper Pharmaceuticals Inc (JNP) Receives Consensus Recommendation of “Hold” from Analysts|
www.americanbankingnews.com - March 10 at 2:45 PM
|Juniper Pharmaceuticals Inc (JNP) Issues Quarterly Earnings Results|
www.americanbankingnews.com - March 8 at 2:21 PM
|Juniper Pharmaceuticals Reports Fourth Quarter and Full-Year 2016 Financial and Operating Results|
us.rd.yahoo.com - March 7 at 10:51 AM
|JUNIPER PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a|
us.rd.yahoo.com - March 7 at 10:51 AM
|Q4 2016 Juniper Pharmaceuticals Inc Earnings Release - Before Market Open|
biz.yahoo.com - March 7 at 10:51 AM
|Juniper Pharmaceuticals to Present at ROTH Conference on March 14, 2017|
finance.yahoo.com - March 6 at 5:38 PM
|Juniper Pharmaceuticals to Report Fourth Quarter and Year-End 2016 Results on March 7, 2017|
finance.yahoo.com - March 1 at 11:30 AM
|Latest version of Dodd-Frank reversal bill would exempt a third of public companies from giving auditor warning|
www.marketwatch.com - February 16 at 5:45 PM
|Juniper Pharmaceuticals Presents Poster at SMFM 2017 on Current Practice Among U.S. Obstetricians to Screen, Define, and Treat a Short Cervix to Prevent Preterm Birth|
finance.yahoo.com - January 26 at 7:49 PM
|Juniper Pharmaceuticals Unveils Strategic and Product Development Objectives for 2017 - Yahoo Finance|
finance.yahoo.com - January 7 at 4:46 AM
|BRIEF-Juniper Pharma will focus on IND-enabling activities for JNP-0201|
www.reuters.com - January 6 at 6:46 PM
|8:01 am Juniper Pharma announced plans for 2017 that are expected to enable the Company to submit Investigational New Drug applications for its hormone-delivery intravaginal ring candidates in the first half of 2018|
us.rd.yahoo.com - January 6 at 6:45 PM
|BRIEF-Juniper Pharmaceuticals prototype formulation development for JNP-0301 is underway|
www.reuters.com - January 5 at 7:22 PM
|JUNIPER PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure,|
biz.yahoo.com - December 23 at 6:19 PM
|Juniper Pharmaceuticals Announces Appointment of Jeffrey Young as Chief Financial Officer - PR Newswire (press release)|
www.prnewswire.com - December 21 at 8:20 AM
|8:01 am Juniper Pharma appoints Jeffrey Young to succeed George Elston as CFO effective Jan 1, 2017|
finance.yahoo.com - December 20 at 11:38 AM
|JUNIPER PHARMACEUTICALS INC Financials|
finance.yahoo.com - November 19 at 5:52 PM
Juniper Pharmaceuticals (JNP) Chart for Monday, May, 29, 2017